Literature DB >> 11184797

Moral hazard in physician prescription behavior.

D Lundin1.   

Abstract

I examine whether the choice made by physicians concerning what drug version--trade-name or generic--to prescribe is subject to moral hazard. I use a data set containing information on exactly what drug and what version was prescribed at a particular patient visit to the physician. The results indicate that physicians' habits and the tastes acquired by patients are important. However, costs also matter. Patients having to pay large sums out-of-pocket are less likely to have trade-name versions prescribed than patients getting most of their costs reimbursed. This indicates moral hazard.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11184797     DOI: 10.1016/s0167-6296(00)00033-3

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  16 in total

1.  Retailing policies for generic medicines.

Authors:  Susana Narciso
Journal:  Int J Health Care Finance Econ       Date:  2005-06

2.  Regulated medical fee schedule of the Japanese health care system.

Authors:  Makoto Kakinaka; Ryuta Ray Kato
Journal:  Int J Health Care Finance Econ       Date:  2013-09-26

3.  Generic substitution: micro evidence from register data in Norway.

Authors:  Dag Morten Dalen; Kari Furu; Marilena Locatelli; Steinar Strøm
Journal:  Eur J Health Econ       Date:  2010-03-06

4.  Entry time effects and follow-on drug competition.

Authors:  Luiz Flavio Andrade; Catherine Sermet; Sylvain Pichetti
Journal:  Eur J Health Econ       Date:  2014-12-12

5.  Generic substitution, financial interests, and imperfect agency.

Authors:  Maurus Rischatsch; Maria Trottmann; Peter Zweifel
Journal:  Int J Health Care Finance Econ       Date:  2013-03-14

6.  Medications prescribing pattern toward insured patients.

Authors:  Ameen Al-Mohamadi; Atika Mohammed Al-Harbi; Areej Mansour Manshi; Mona Majdi Rakkah
Journal:  Saudi Pharm J       Date:  2013-01-30       Impact factor: 4.330

7.  The impact of health insurance expansion on physician treatment choice: Medicare Part D and physician prescribing.

Authors:  Tianyan Hu; Sandra L Decker; Shin-Yi Chou
Journal:  Int J Health Econ Manag       Date:  2017-02-06

8.  Patient Copayments, Provider Incentives and Income Effects: Theory and Evidence from the Essential Medications List under China's 2009 Healthcare Reform.

Authors:  Brian K Chen; Y Tony Yang; Karen Eggleston
Journal:  World Med Health Policy       Date:  2017-03-16

9.  Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data.

Authors:  Maria-Isabel Farfan-Portet; Carine Van de Voorde; France Vrijens; Robert Vander Stichele
Journal:  Eur J Health Econ       Date:  2012-03-18

10.  Do decision support systems influence variation in prescription?

Authors:  Judith D de Jong; Peter P Groenewegen; Peter Spreeuwenberg; Gert P Westert; Dinny H de Bakker
Journal:  BMC Health Serv Res       Date:  2009-01-30       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.